{"prompt": "['26', 'MC1488 WEE1', 'MCCC', 'Table 4.2: Test Schedule for HMA failure MDS patients', 'Active Monitoring Phase', '<14 days', '7 days', 'Cycles 1', 'Cycle 2 Days 1,', 'Cycles 3+ Day 1', 'EOS\u00b2', 'prior to', 'prior to', 'Days 1, 8,', '15, and 28 (+ 3', 'and Beyond(+/-', 'Tests and procedures', 'registration', 'registration', '15, &', 'days) 10, 12', 'days) 10,', '12', '28(+3', 'days) 12', 'History and exam, wt, PS,', 'X', 'X', 'X', 'X', 'X', 'vitals', 'Height', 'X', 'Adverse event assessment', 'X', 'X', 'X', 'X', 'X', 'Hematology group', 'WBC', 'ANC', 'X', 'X', 'X', 'X', 'X', 'Hgb', 'PLT', 'Chemistry group: sodium,', 'potassium, calcium,', 'creatinine,', 'bicarbonate, glucose,', 'chloride, albumin,', 'X', 'X', 'X', 'X', 'X', 'BUN, alkaline', 'phosphatase, AST,', 'ALT, total protein,', 'total bilirubin, LDH', 'Serum Erythropoietin', 'X', 'level', 'Serum pregnancy test', 'X', 'Bone marrow biopsy and', 'aspirate procedure', 'X\u00b3', 'X\u00b3', 'X6', 'X\u00b9', '(cytogenetics or', 'FISH9', 'Blood specimens (see', 'X4', 'X4', 'X4', 'X4', 'X4', 'Section 14.0)R', 'Buccal swab (see Section', 'X']['27', 'MC1488 WEE1', 'MCCC', '14.0) R', 'Bone marrow aspirate', 'research specimens', 'X6', 'X5', 'X5', 'X5', '(see Section 14.0)R', 'Patient Questionnaire', 'X', 'X8', 'X8', 'X8', 'X', 'Booklet8', 'ECG (12 lead)', '11', 'X', 'X', '1.', 'For women of childbearing potential only', '2.', '30 days (+/-3days) post last dose of study drug', '3. Marrow biopsies only to be done at End of cycle 2, End of cycle 4, at time of suspected CR/CRi and thereafter at physician discretion as clinically indicated (i.e. disease progression).', '4.', 'Blood specimens for research sampling to be collected as defined in Section 14.', '5.', 'Research marrow samples (aspirates) to be done at times of clinical standard of care marrow tests at End of cycle 2, End of cycle 4, at time of suspected CR/CRi or disease', \"progression and thereafter at physician discretion as clinically indicated. A sample will be obtained at end of study (EOS) if a bone marrow is performed as part of patient's\", 'standard of care; sample will be collected per section 14.0', '6.', '< 28 days prior to registration; for patients with an outside marrow biopsy within 4 weeks of study start, outside results can serve as baseline after review at Mayo Clinic. In', 'these cases, samples for correlative laboratory studies will be drawn from peripheral blood prior to study start.', '7.', 'Bone marrow at end of study is only to be done at physician discretion and is optional. Progression marrow can be used as EOS marrow if patient is taken off trial based on the', 'results.', '8.', 'Patient questionnaire booklet must be used; copies are not acceptable for this submission. Booklet should be completed by patient prior to review of treatment response and', \"discussions of patient's general health since last treatment evaluation. Booklets to be completed at end of all cycles.\", '9.', 'Either conventional cytogenetics or FISH panel (or both based on physician discretion) for MDS should be performed at baseline. If diploid cytogentics at baseline subsequent', 'cytogenetic studies may be omitted unless disease progression is suspected. For FISH based cytogenetic assessments, an entire MDS FISH panel should be performed at', 'baseline, while on subsequent marrows only positive specific FISH abnormalities/probes need to be repeated unless disease progression is suspected.', '10. Prior to the start of treatment.', '11. ECG to be repeated if cardiac symptoms occur or as otherwise defined in the test schedule.', '12. Day 1 assessments do not need to be repeated if pre-registration or Day 28 assessments completed within 48 hours of Day 1.', 'R', 'Research funded (see Section 19.0).']\n\n###\n\n", "completion": "END"}